Littérature scientifique sur le sujet « Lympohma »

Non-Hodgkin's lymphomas (NHL) are the second most frequent malignancies in AIDS patients. The majority of NHL associated with AIDS involves extranodal sites, especially the digestive tract and the central nervous system. Primary liver lymphoma (PLL) is an uncommon neoplasm among these patients. Ultrasonography and computed tomography scans may be helpful in the diagnosis of focal hepatic lymphoma. Image-guided fine-needle biopsy with histopathology of the liver lesions is the gold standard for the diagnosis of hepatic lymphoma. We report a case of PLL as the initial manifestation of AIDS in a patient without any previous infection by hepatitis C or B virus, presented as multiple and large hepatic masses.

Abstract Introduction In classical Hodgkin Disease, Reed Sternberg cells reacts with antibodies against a granulocyte associated antigen, CD15/CD30. So expression of immunochemistries CD15 and CD 30 in patients,suspecting for HD, has quite significant diagnostic value. Aim To find out relevance of CD15/CD30 expression in relation to clinical outcome in patients of Hodgkin's disease. Methods and Material A total of 301 patients of Hodgkin' disease from stage I to stage IV treated in Shaukat Khanum hospital during last 8 years, were reviewed. Data was analyzed concerning age, gender, histopathology, staging, immunochemistry and outcome. Results: Among these 301 patients, male to female ratio was 4.3:1.The mean age was 10.01years Maximum patients presented in stage III i.e 40.2 %. Total 55 (18.2%) patients were reported positive for CD 15 and 261 (86.7 %) for CD 30. Amongst CD 15 positive patients, 1.8% received palliation, 16.3% showed Primary progressive Hodgkin's lymphoma ( PPHL ),16.3% showed relapse. Amongst CD 15 negative patients, no patients received palliation, 9.47% showed PPHL, 15.7% showed relapse. Amongst CD 30 positive patients, 0.38% pts received palliation, 7.66% showed PPHL, 12.2% showed relapse. Conclusion: There is diagnostic significance of CD15/CD 30 in Hodgkin's Disease but the prognostic significance of these immunochemistries could not be proven. Disclosures No relevant conflicts of interest to declare.

I linfomi non-Hodgkin a cellule T (T-NHL) rappresentano un gruppo eterogeneo di neoplasie a decorso aggressivo, caratterizzate da resistenza alla terapia e prognosi avversa. L’obiettivo del progetto era di identificare e sviluppare nuovi approcci nelle aree di maggior bisogno nell’ambito dei T-NHL. Abbiamo valutato l’esito dei pazienti affetti da T-NHL trattati a Bergamo negli ultimi 20 anni, focalizzando il ruolo del consolidamento con trapianto autologo. Oltre a confermare la prognosi avversa dei T-NHL, i nostri risultati hanno permesso di identificare che la risposta primaria, più che la terapia di consolidamento (i.e. trapianto autologo), è il fattore decisivo per la prognosi. Ci siamo quindi focalizzati sulla valutazione preclinica di due nuovi approcci terapeutici. Il primo approccio si è focalizzato sull’utilizzo dell’anticorpo anti-tenascina-C Tenatumomab (ST2146), attualmente in sviluppo clinico per applicazioni di radio-immunoterapia. In una coorte di 100 pazienti con T-NHL abbiamo dimostrato la presenza di tenascina-C in quasi tutti i casi e la sua correlazione con parametri di aggressività clinica. La seconda strategia si basa sull’osservazione che, vista la chemiorefrattarietà della maggior parte dei T-NHL, approcci terapeutici alternativi come l’utilizzo dell’enzima L-asparaginasi (ASNase) non sono mai stati riportati in questo contesto. Abbiamo quindi valutato in un pannello di linee cellulari di T-NHL (HH, Hut-78 and Karpas299) e linfomi a cellule NK (NK-92) l’attività di tre diverse forme di ASNase correlando i risultati con due noti meccanismi di resistenza i.e. l’espressione di asparagin e glutamin sintetasi (ASNS e GS). ASNase ha mostrato segni di attività in vitro correlata con i meccanismi di resistenza valutati. La valutazione immunoistochimica di ASNS e GS su biopsie di pazienti con T-NHL, inoltre, ha mostrato che molti casi sono caratterizzati da una bassa espressione dei due enzimi. Questi risultati suggeriscono che ASNase potrebbe essere utile in casi selezioni di T-NHL ma ulteriori studi clinici e laboratoristici sono necessari. In conclusione, il nostro studio, partendo dalla revisione critica della nostra coorte di pazienti, ha dimostrato l’utilità in preclinica di due nuovi approcci terapeutici nell’ambito dei T-NHL, ponendo le basi per successivi studi clinici e preclinici.
T-cell non-Hodgkin lymphomas (NHL) are a heterogeneous and rare group of aggressive malignancies, characterized by treatment resistance and poor outcome. Aim of the project was to identify and to develop new strategies to address the areas of unmet need in T-cell NHL. We firstly evaluate the outcome of T-cell NHL patients treated at Bergamo in the last two decades focusing on the role of front-line stem cell transplant consolidation. Along with the confirmation of the general poor prognosis of T-cell NHL, our results identified primary response rather than post-remission programs (i.e. stem cell transplant) as the crucial determinant of outcome. Thus, we focused on improving induction therapy evaluating two different strategies in preclinical setting. The first strategy involved the potential use of Tenatumomab (ST2146), an anti tenascin-C monoclonal antibody currently under clinical development for radio immunotherapy. In a cohort of 100 cases of T-cell NHL we find that tenascin-C is expressed in nearly all of the cases, the expression was correlated with clinical aggressiveness. The second strategy moved from the observation that, while T-cell NHL is often resistant to multi-chemotherapy induction regimens, the potential role of alternative therapies such as the enzymatic drugs L-asparaginase (ASNase) has not been assessed in this setting. Thus, we evaluated the in vitro activity of three different forms of ASNase in a panel of cell lines derived from T-cell NHL (HH, Hut-78 and Karpas299) and NK-cell lymphomas (NK-92) and correlated the activity with known mechanism of resistance i.e. asparagine and glutamine synthetase (ASNS and GS) expression. ASNase shows signs of in vitro activity and its activity correlated with the evaluated resistance mechanisms. The immunohistochemical expression of ASNS and GS in T-cell NHL samples showed that several cases were characterized by a very low ASNS and GS expression. Our results indicates that ASNase may be useful in selected